PRESS RELEASE:
MEMPHIS, Tenn.–(BUSINESS WIRE)–January 12, 2016–
Entac Medical Inc. announced today that the US Patent and Trademark Office has issued a patent on its platform technology to predict gastrointestinal impairment (GII) in surgical patients. The company has also received a Notice of Allowance from the China Patent and Trademark Office.
The noninvasive technology detects a biological signal that is highly correlated with the development of GII; primarily postoperative ileus, an acute paralysis of the gastrointestinal tract causing nausea and vomiting as well as abdominal distention and pain. PrevisEA, Entac’s lead device to predict GII, has demonstrated high accuracy in the risk stratification of patients with 95% specificity and 83% sensitivity in the clinical setting.
With onset occurring 2-6 days after surgery, GII is a common condition of many types of surgery, especially in colorectal surgery where approximately 25% of 2 million patients are affected annually in the US alone. The inability to predict patients at risk for GII often unnecessarily increases length of hospital stay by 4-6 days and causes readmission rates in excess of 20%, making it one of the most prevalent conditions for readmissions of surgical patients. The financial impact of over-utilization of hospital resources is estimated to be $10-$15 billion per year in the US.
Buddy Lyons, CEO of Entac, stated, “We continue to strengthen our intellectual property in the US and all major global jurisdictions. Given that there are no devices or tests available that would enable development of a standard of care for this large, underserved patient population, Entac is moving expeditiously to complete development of PrevisEA. Based on discussions with the FDA, we believe PrevisEA could be cleared for marketing in 18-24 months.”
Entac is planning additional applications of the platform technology in gastrointestinal predictive medicine and diagnostics.
About Entac Medical Inc.
Entac Medical is a predictive analytics company developing noninvasive devices for the prediction and diagnosis of gastrointestinal and other medical conditions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160112005265/en/
Entac Medical Inc.
Buddy Lyons, CEO, 901-292-3420
blyons@entacmedical.com